35. FTC Docket No. C-3945. In the Matter of Abbott Laboratories and Geneva Pharmaceuticals, Inc. Complaint. 2000, May 26. Available at: http:// http://www.ftc.gov/os/2000/05/c3945complaint.htm.

36. FTC Docket No. 9293. In the Matter of Hoechst Marion Roussel, Inc, Carderm Capital LP, and Andrx Corp. Consent Order and FTC Commission Actions. 2001, May 8, 11. Available at: http:// http://www.ftc.gov/os/2001/05/hoechstdo.htm and http:// http://www.ftc.gov/opa/2001/05/fyi0130.htm.

37. FTC Docket No. 9297. In the Matter of Schering-Plough Corp, Upsher-Smith Laboratories, and American Home Products Corp. 2001 November 20. Available at: http:// http://www.ftc.gov/os/adjpro/d9297/011109stip.pdf

39. In Re Cardizem CD Antitrust Litigation, 332 F3d 896 (6th Cir 2003).

40. In re Terazosin Hydrochloride Antitrust Litigation, 164 F Supp 2d 1340 (SD Fla 2000).

41. Valley Drug Co. v Geneva Pharmaceuticals, Inc, 344 F3d 1294 (11th Cir 2003).

42. Jefferson Parish Hospital Dist No. 2 v Hyde, 466 US 2 (1984).

43. Sandoz Pharmaceuticals Corp, 115 FTC 625 (1992) (consent order). Summarized at: http:// http://www.ftc.gov/bc/rxupdate021108.htm.

44. Horton TJ. Protecting Your Life Sciences and Biotech Licenses from the Specter of the Antitrust Laws. Licensing J. 2005 March:1.

45. Carson P, Jackson M, Mandrgoc M. Maximizing prosperity through strategic licensing. Paper presented at: American Conference Institute Conference on Pharma and Biotech In-Licensing Co-Development and Co-Promotion Agreements; 2002 October 21; New York, NY.